Novartis AG

NOVN

CH0012005267

Pharmaceuticals

Market Closed - Swiss Exchange Other stock markets 11:30:00 2026-01-19 EST			5-day change	1st Jan Change
115.56 ^CHF	-0.03%		+1.51%	+5.44%

01-19	Switzerland's Novartis Secures US FDA Breakthrough Designation for Sjögren's Candidate Ianalumab	MT
01-18	Novartis Lands US FDA Breakthrough Therapy Classification for Ianalumab in Sjögren's Disease	MT

Novartis target price raised after upgrades

Following strong execution and two 2025 outlook upgrades, the analyst lifts estimates and raises the target price, citing high-margin growth areas, robust R&D, disciplined bolt-on acquisition strategy, and solid balance sheet support to sustain mid-term ambitions.

Published on 12/05/2025 at 11:23 am EST - Modified on 12/05/2025 at 10:49 am EST

Alphavalue

Novartis target price raised after upgrades

This Alphavalue article, the European leader in independent research, is only available to subscribers .

Alphavalue is exclusively on MarketScreener.
To unlock the article, SUBSCRIBE!

Already a customer? Log In

Latest news about Novartis AG

01-19	Switzerland's Novartis Secures US FDA Breakthrough Designation for Sjögren's Candidate Ianalumab	MT
01-18	Novartis Lands US FDA Breakthrough Therapy Classification for Ianalumab in Sjögren's Disease	MT
01-16	Novartis Ianalumab Receives Fda Breakthrough Therapy Designation for Sjogren's Disease	CI
01-16	Novartis Receives US FDA Breakthrough Therapy Designation for Ianalumab to Treat Sjogren's Disease	MT
01-16	Novartis - Ianalumab receives FDA breakthrough therapy designation for Sjögren's disease	RE
01-16	Novartis ianalumab receives FDA Breakthrough Therapy designation for Sjögren's disease	DJ
01-16	NOVARTIS AG : UBS sticks Neutral	ZD
01-16	NOVARTIS AG : Deutsche Bank keeps its Buy rating	ZD
01-15	Trump Launches Health Care Plan to Reduce Drug Costs	MT
01-15	Pharma sector doubles down on AI amid hopes of slashing costs, timelines	RE
01-15	NOVARTIS AG : Barclays remains Neutral	ZD
01-14	Dr. Reddy's Laboratories Launches Olopatadine Hydrochloride Ophthalmic Solution in US	MT
01-14	SciNeuro Grants Novartis Rights for Alzheimer's Disease Drug	MT
01-14	Swiss stocks - Factors to watch on January 14	RE
01-13	Travere shares fall as US FDA extends review of rare kidney disease drug	RE
01-13	Novartis eyes more bolt-on acquisitions, CEO says	RE
01-13	Global drugmakers rush to boost US presence as tariff threat looms	RE
01-13	Swiss stocks - Factors to watch on January 13	RE
01-12	Novartis Saudi Partners with Saudi Scientific Organization on Chronic Urticaria Awareness Campaign	MT
01-12	Novartis AG Presents at 44th Annual J.P. Morgan Healthcare Conference, Jan-12-2026 09:00 AM
01-12	Novartis eyes more bolt-on acquisitions, CEO says	RE
01-12	Swiss Market Index Begins Week Flat; UBS, Novartis Edge Lower	MT
01-12	Novartis to Do Value-Creating Bolt-Ons	CI
01-12	SciNeuro, Novartis sign $1.7 billion licensing deal to develop Alzheimer's drugs	RE
01-12	Kyverna Therapeutics, Inc. Appoints Christi Shaw as Executive Chairperson of the Board, Effective January 12, 2026	CI

Chart Novartis AG

Duration

Period

NOVN: Dynamic Chart

Company Profile

Novartis AG is one of the world's leaders in the design, manufacturing, and marketing of pharmaceutical products. Net sales break down by therapeutic area as follows: - oncology (29.3%); - immunology (18.5%); - cardiovascular, renal and metabolic diseases (17%); - neuroscience (9.4%). The remaining net sales (25.8%) are from contract manufacturing of pharmaceutical products. At the end of 2024, Novartis AG had over 30 production sites worldwide. Net sales are distributed geographically as follows: Europe (30.9%), the United States (42%), Asia/Africa/Australasia (20%), Canada and Latin America (7.1%).

Employees

75,883

Sector

Pharmaceuticals

Calendar

02-03 - Q4 2025 Earnings Release

More about the company